HXR9 peptide acting to block HOX / PBX binding

HXR9 peptide acting to block HOX / PBX binding

The HOX genes are a family of homeodomain-containing transcription factors that determine the indetitity of cells and tissues during embryonic development, and are also known to be deregulated in a number of cancers. We use a novel antagonist (HXR9) that disrupts the interaction between HOX proteins and their co-factor PBX, and can induce apoptosis in a variety of aggressive, difficult to treat cancers. HXR9 has been tried in a number of cancer models in small mammals and looks promising.

Patents:
US 11,993,978
JP 2,008,518,963

Type of Offer: Licensing

[CONTACT THE OWNER OF THIS TECHNOLOGY]

[NEXT TECHNOLOGY][MORE BIOMEDICAL TECHNOLOGIES]
[MORE LIFE SCIENCES TECHNOLOGIES]

Innovation
Order Form

Life is getting simpler
for R&D departments that can articulate their innovation needs.
[CLICK HERE TO ORDER]

HXR9 peptide acting to block HOX / PBX binding

Innovation Order Form

Innovation
Order Form